The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
iwMDS/iwMPN 2026 | Should we transplant patients with TP53-mutated MDS? The case in favor
Talha Badar, MD, Mayo Clinic, Jacksonville, FL, argues in favor of allogeneic stem cell transplantation (allo-SCT) for selected patients with TP53-mutated myelodysplastic syndromes (MDS). Dr Badar highlights the potential for long-term survival despite adverse disease biology, emphasizing the importance of molecular risk, disease burden, patient fitness, and post-transplant strategies to reduce relapse. This presentation took place at the 4th International Workshop on Myelodysplastic Syndromes & Myeloproliferative Neoplasms (iwMDS/iwMPN) 2026, held in Washington, DC.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
